Document is current
Any future updates will be listed below
-
Authors
Ikewaki, Nobunao
Ikeue, Yasunori
Nagataki, Mitsuru
Kurosawa, Gene
Dedeepiya, Vidyasagar Devaprasad
Rajmohan, Mathaiyan
Vaddi, Suryaprakash
Senthilkumar, Rajappa
Preethy, Senthilkumar
Abraham, Samuel J. K. https://orcid.org/0000-0003-2646-2687
- License Information
-
More Information
Article History
Received: 14 February 2022
Accepted: 30 November 2022
First Online: 11 December 2022
Declarations
:
: The protocol approval was obtained from the ethics committee of Toya Laboratory, HOKUDO Co., Japan (Ref no: HKD47047). The study was conducted in accordance with the HOKUDO Animal Experiment Regulations following the Act on Welfare and Management of Animals (Ministry of the Environment, Japan, Act No. 105 of October 1, 1973), standards relating to the care and management of laboratory animals and relief of pain (Notice No.88 of the Ministry of the Environment, Japan, April 28, 2006) and the guidelines for proper conduct of animal experiments (Science Council of Japan, June 1, 2006). All animal experiments took place at Toya Laboratory, HOKUDO Co., Hokkaido, Japan.
: Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.
